Acute myeloblastic leukemia (AML) is characterized by uncontrolled proliferation with the bone marrow (BM) of malignant myeloid progenitors arrested in their maturation process and the egress of these abnormal cells into the circulation. There is evidence that neutrophil production is a balance between the proliferative action of granulocyte-colony-stimulating factor (G-CSF) and a negative feedback from mature neutrophils. Recently, there have been reports on mutations in neutrophil elastase (ELA2) gene in genomic DNA of cyclic neutropenia. These patients developed acute myeloblastic leukemia. Therefore, we hypothesized that elastase may play role in the abnormal AML. Peripheral blood was obtained from 42 patients with acute myeloblastic leukemia and 30 healthy individuals. Total RNA was isolated using RNA standard techniques from freshly separated cells by polymorphoprep. RNA was analyzed by employing PCR amplification of reverse transcribed using a total of ten specific primers. We amplified five exons of ELA2 gene separately and sequenced each exon. Mutational analysis was carried out by directed capillary sequencing method. We found no mutation in 42 Acute myeloblastic leukemia patients compared to healthy individuals. Interestingly, we found heterozygote 50% single nucleotide polymorphism (SNP) in exon II codon 44 of healthy individuals but not in AML patients. It was a silent mutation G to A substitution but no changes in amino acid sequences. The codon sequence was GCG that changed to GCA.
Acute myeloblastic leukemia (AML) is characterized by uncontrolled proliferation with the bone marrow (BM) of malignant myeloid progenitors arrested in their maturation process and the egress of these abnormal cells into the circulation.
There is evidence that neutrophil production is a balance between the proliferative action of granulocyte-colony-stimulating factor (G-CSF) and a negative feedback from mature neutrophils. Recently, there have been reports on mutations in neutrophil elastase (ELA2) gene in genomic DNA of cyclic neutropenia. These patients developed acute myeloblastic leukemia. Therefore, we hypothesized that elastase may play role in the abnormal AML. Peripheral blood was obtained from 42 patients with acute myeloblastic leukemia and 30 healthy individuals. Total RNA was isolated using RNA standard techniques from freshly separated cells by polymorphoprep. RNA was analyzed by employing PCR amplification of reverse transcribed using a total of ten specific primers. We amplified five exons of ELA2 gene separately and sequenced each exon. Mutational analysis was carried out by directed capillary sequencing method. We found no mutation in 42 Acute myeloblastic leukemia patients compared to healthy individuals. Interestingly, we found heterozygote 50% single nucleotide polymorphism (SNP) in exon II codon 44 of healthy individuals but not in AML patients. It was a silent mutation G to A substitution but no changes in amino acid sequences. The codon sequence was GCG that changed to GCA.
Acute myeloblastic leukemia (AML) is characterized by uncontrolled proliferation within the bone marrow (BM) of malignant myeloid progenitors arrested in their maturation process and the egress of these abnormal cells into the circulation(1).
Leukocyte or neutrophil elastase (NE) is a serine protease stored in azurophilic granules of myeloid cells and is released upon activation and degranulation (2) . There is evidence that neutrophil production is a balance between the proliferative action of granulocyte-colony-stimulating factor (G-CSF) and a negative feedback from mature neutrophils (3) . Two neutrophil serine proteases have been implicated in granulopoietic regulation: proteinase 3 inhibits granulocyte macrophagecolony-forming unit (CFU-GM) growth, and elastase mutations cause cyclic and congenital neutropenia (FR) (4) (5) . Elastase inhibits CFU-GM in methyl cellulose culture (6) . In 1991 Shellard et al purified an in vitro inhibitor of normal myelopoiesis using a monoclonal antibody directed to a common antigen of myelogenous leukemia (CAMAL). However, at the stage of committed progenitor of neutrophils and monocytes granulocyte macrophage colony forming unit (CFU-GM), G-CSF is the only growth factor required for neutrophil granulopoiesis (7) . Through positional cloning studies it was found that the locus was mapped to chromosome 19pI3.3, a region containing the genes for three neutrophil proteases: azurcidin, proteinase 3, and neutrophil elastase (so called ELA2) (8) . Neutrophil elastase is a potent 218 amino acid protease synthesized by CD34+ precursor cells during the initial stage in the production of the primary granules of the neutrophil (9) .
Mature neutrophils utilize the stored enzyme in phagolysosomes or release neutrophil elastase when the neutrophil is stimulated or has been lysed (10) (11) . Recently, there has been a report on detected mutations in neutrophil elastase (ELA2) gene in genomic DNA of cyclic neutropenia. These patients developed acute myeloblastic leukemia. It has also been reported that mutations in the gene for neutrophil elastase ELA2 seems to be involved in the etiology of acute myeloblastic leukemia (3) . As an initial step towards understanding neutrophil elastase gene expression, the purpose of the present study is to characterize the EIA2 mutations at RNA level and amino acid changes in protein level of the EIA2 for better understanding of the role of EIA2 gene encoding in pathophysiology of acute myeloblastic leukemia. Therefore, we hypothesize that abnormal elastase may play role in the AML.
MATERIALS AND METHODS
Normal human peripheral blood (PBL) cells from 42 malignant acute myeloblastic leukemia (AML) patients and 30 healthy individuals (as controls) were obtained. The diagnosis of leukemia was based on routine morphologic evaluation, immunophenotyping, and cytochemical smears using French-American-British (FAB) classification. Forty-two newly diagnosed AML patients and thirty healthy individuals as a control group took part in this study.
All patients and control subjects were studied according to the declaration of Helsinki. Written informed consent was obtained from each individual. The consent for this study was obtained from the parents ofthe patients under the auspices of the human subjects committee of the Tehran Medical Sciences University. Healthy individuals with nonnal blood counts served as controls.
Peripheral blood samples (4 ml) were obtained from the cubital vein and collected in cell preparation tubes containing anticoagulant. Peripheral polymorphoneuclear cells were isolated by polymorphoprep (Axis-Shield Poe AS, Oslo, Norway).
The polymorphoneuclear layer was collected and washed three times in phosphate buffer saline (PBS). The total mRNA was isolated from lymphocytes by RNA blood minikit (Roach, Germany), and the amount and purity of the RNA was determined by spectrophotometry.
Elastase II mRNA expression was determined by RT-PCR. Total RNA amounting to 1500 ng was reverse transcribed into first-strand cDNA by using random hexamers and 2-5 units of multi scribe (recombinant Moloney murine leukemia virus) reverse transcriptase in a final volume of 40 ul (12) . Primers for exons ELI, EL2, EL3, EL4, EL5 and the whole exon as control were designed using primer express software to exclude amplification of genomic DNA and pseudo genes. cDNA of 75 ng was used for PCR amplification in final volume of 25 ul with I unit of Taq DNA polymerase (Roach, Germany), PCR was carried out in a PCR machine (Techneh, USA). For each of the 5 exons and PCR reactions, negative control (water) and positive control (pooled cDNA) from several healthy blood donors (peripheral blood polymorphoneuclear) were used in parallel with every set of experiments.
-actin was used to amplify a 140 base pair fragment that served as an internal standard for cDNA preparation.
-actin primer pair was used in the PCR to normalize the concentration of cDNA. A liquate of each amplification reaction was loaded in ethidium bromide stained in 1.5% agarose gels, and electrophoresis performed at 100 v for 45 min to confirm the expected size of the amplified fragments. Analysis of mutations were performed by capillary sequencing. Each product of Elastase II gene (Exon 1 to 5) was sequenced by DNA sequencer ABI 3700 capillary system (Applied, Biosystem, USA).
Products were cleaned using the PCR purification kit (Qiagen, Germany) and were directly sequenced in both directions using the same primers. For the 
RESULTS
The results of the present study reveal that all different elastase II gene exons (ELA 1-5) were expressed in peripheral blood polymorphoneuclear cells in 30 healthy individuals. We then carried out RT-PCR on 42 samples from acute myeloblastic leukemia (AML) patients. Fig. 1 shows agarose gel electrophoresis of RT-PCR produces amplifications in AML patients. Elastase II gene specific amplification products were different in size exonl, 2 (211bp), exon 3 (146bp), exon 4 (247bp), exon 5 (176 bp). Moreover, we designed primers to amplify whole exon as a positive control (735bp). Elastase II gene in peripheral blood polymorphonuclear cells were expressed in 30 normal individuals and 42 acute myeloblastic leukemia (AML) patients. Our results presented here provide direct evidence that AML cells express ELA2 gene. The specificities of the obtained PCR products for the respective ELA2 fragments were confirmed by capillary sequencing analysis.
The PCR products were tested by blasting against the entire human genome (NCBI-national center for biotechnology information 2007) to exclude sequencing at unwarranted sites (13). Mutational analysis was carried out by capillary sequencing. Each product of Elastase II gene (Exon 1 to 5) was sequenced by DNA sequencer ABI 3700 capillary system. For each mutation found, at least 30 healthy controls were included.
We found no mutations in different exons of Elastase 11 gene encoding in 42 acute myeloblastic leukemia patients compared to 30 healthy individuals. It is thus most likely that a novel 50% frequency of polymorphism in exon 2 occurs (GCG 44-NCBI, GCA44-Iranian) in the Iranian population which had never been reported previously. Moreover, only one coding sequence change in the gene for neutrophil elastase was observed in 30 controls from normal individuals, and this change is presumed to represent a polymorphism because of its non-appearance also in acute myeloblastic leukemia. Table I shows single nucleotide polymorphism (SNP) percentage of homozygote and heterozygote sequence in codon 44 of exon 2 in AML and Iranian healthy individuals. Our previous study showed mutations in myeloid lineage arrest, such as Kostmann, CN, compared to healthy individuals (14) (15) . Fig. 2 shows the percentage of mutations and SNP in myeloid lineage from left (arrest) to right (hyper proliferation) in Kostmann, cyclic neutropenia (CN), healthy individuals and AML patients.
DISCUSSION
Recently, we, as well as others, began to identify the role ofELAII mutations in the maturation of the myeloid lineage. Previous studies have suggested that the pathophysiology of congenital neutropenia may be related to mutations of elastase II gene (4, 16 ). The findings, reported previously, suggest a primary role for mutations of neutrophil elastase in causing most, but not all, cases of cyclic neutropenia. Of interest, heterozygous germ-line mutations in the ELA2 gene encoding human leukocyte elastase have been associated with several inherited neutropenia and Kostmann diseases, which are characterized by a severe impairment in neutrophil release into the circulation (14) (15) . This protease is normally synthesized and packaged in promyelocytes at an early stage in neutrophil development (17) (18) . Neutrophil elastase has many recognized and possible substrates, including coagulation proteins, growth factors, and intracellular signaling molecules (19) (20) .
The finding that elastase, among other proteolytic enzymes such as cathepsin G and MMPS, participates in the process of G-CSF-induced mobilization of normal stem cells, progenitors, and maturing cells led to hypothesize that the abnormally high levels of elastase in AML patients' plasma may facilitate the cells' egress into the circulation (21) (22) . Elastase, along with other azurophil (primary) granule proteins, is synthesized early in myelopoiesis, during the myeloblast to promyelocyte transition. They show that the amount of elastase in the bone marrow and plasma ofAML patients is dependent on the maturation stage ofthe leukemic clone (23) .
Other studies confirm that AML patients have higher levels of elastase in the blood compared to healthy individuals. Moreover, they found a significant positive correlation between the level of blood plasma elastase and the number of blast cells present in the circulation (24) .
These observations suggest that AML cells secrete elastase both in the 8M and in the blood after their egress. Of interest, AML patients with no dissemination of blasts in the circulation had normal levels of elastase in the peripheral blood (25) .
In the present study, we found no mutations and no polymorphism of elastase II gene in AML patients compared to Kostmann, Cyclic Neutropenia and healthy individuals (Fig. 2) . These results suggest a role of elastase II mutation at the level of elastase II in promoting arrest (neutropenia) or hyper proliferation ofAML cells. Therefore, a high level of elastase expressed by AML cells may promote their transendothelial migration and egress by increasing their interactions with bone marrow endothelial cells (26) (27) . However, our data demonstrate that Elastase II hyper mutation arrests the myeloid lineage (Kostmann, CN) and there is no mutation in the hyper proliferative myeloid lineage (AML). Moreover, other studies show decreased levels of Elastase II in arrest and an increased level of Elastase II in hyper proliferation (AML).
This study is the first report at RNA level of ELA2 mutations in patients with AML. A mutation in the ELA2 gene was not detected in 42 apparently AML patients. No mutations were identified in at least 30 healthy controls, but 50% frequency in polymorphisms was detected in healthy individuals. These results are compatible with those published previously, showing that a high level of ELA2 is caused in AML (14) (15) (22) (23) (24) . The pathogenicity of mutations in ELA2 remains a mystery.
Experiments in which the mutant enzyme has been transfected into cell lines (rat basophilic cells RBL-l) and murine myeloblasts (32D) have shown reduced levels of elastase activity in some patients (28) . However, other investigators have reported reduced elastase activity as a more general phenomenon in congenital neutropenia (29) .
Lane and Loy showed that the fusion protein promyelocytic leukemia (APL) is cleaved by neutrophil elastase and that NE-deficient mice are partially protected from development of APL (30) . It appears likely that pathogenesis of this disease is due to an alteration of function in the mutant protein, allowing the enzyme to bind to a novel substrate involved in myelopoisis changing its binding to an intracellular inhibitor. An alternative explanation may relate to changes in intracellular packaging.
In conclusion, our data demonstrate that Elastase II has no mutation in myeloid hyper proliferate AML patients compared to other myeloid lineage arrest such as Kostmann and CN which had mutations. A better understanding of the role of elastase in AML cell biology will possibly lead to a new therapeutic approach for AML based on specific inhibitory molecules of elastase.
